Business Wire

BRAINLAB

Share
Brainlab ExacTrac Integrates Varian’s PerfectPitch to Enable Highly Accurate Radiosurgery Treatments With Advanced 6D Correctional Accuracy

Brainlab released ExacTrac® 6.2, a new version of its successful room-based patient positioning system providing full interoperability with the PerfectPitch™ six-degrees of freedom couch from Varian Medical Systems. This full integration enables customers who have a Varian TrueBeamTM linear accelerator equipped with PerfectPitch and ExacTrac to reap the combined benefits of the two systems. Clinicians are now able to utilize the highly accurate patient positioning and monitoring capabilities of ExacTrac with the precise 6D robotic alignment of Perfect Pitch for all radiosurgery cases in the brain and body.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161215005492/en/

“With a rise in non-coplanar treatments and the usage of single isocenter radiosurgery, the interaction of 6D correction through PerfectPitch with the room-based imaging of ExacTrac will allow our customers to create accurate and reproducible treatments,” said Stephan Froehlich, Vice President, R&D Radiosurgery, Brainlab.

The first installations for the new integrated environment were completed in the United States at The Hospital of Central Connecticut and at Royal Surrey Hospital, in the United Kingdom. Successful patient treatments were reported at both institutions. Dr. Tom Jordan, Head of Radiotherapy Physics at Royal Surrey Hospital commented, “Combining these two technologies is what I always wanted for my radiosurgery system. I can now finally utilize ExacTrac and OBI interchangeably for initial setup and continue to monitor with ExacTrac for intra-fraction motion as we rotate the couch.”

“For our CNS patients we want to carefully evaluate patient motion during treatment,” said Neal Goldberg, MD, Chief Radiation Oncologist at The Hospital of Central Connecticut. “Having the ability to always correct deviations with 6D sub-millimetric accuracy, independent of gantry and couch position, gives me the confidence I needed to treat any tumors in the brain and spine.”

ExacTrac by Brainlab is an in-room X-Ray based positioning and monitoring system that detects intra-fractional tumor motion during treatment delivery, regardless of the couch angle or gantry position. Instantaneous X-Ray imaging with proprietary 6D fusion provides fast and highly accurate positioning information and reduces the possibility of geographical miss due to patient motion or internal anatomical shifts.

About Brainlab

Brainlab, headquartered in Munich, develops, manufactures and markets software-driven medical technology, enabling access to advanced, less invasive patient treatments.

Core products center on information-guided surgery, radiosurgery, precision radiation therapy, digital operating room integration, and information and knowledge exchange. Brainlab technology powers treatments in radiosurgery and radiotherapy as well as numerous surgical fields including neurosurgery, orthopedic, ENT, CMF, spine and trauma.

Privately held since its formation in Munich, Germany in 1989, Brainlab has more than 9,000 systems installed in about 100 countries. Brainlab employs 1,300 people in 18 offices worldwide, including 320 Research & Development engineers, who form a crucial part of the product development team.

To learn more, visit brainlab.com.

Contact:

Brainlab
Anna Bliss, +49 89 991 568 172
Marketing Associate
anna.bliss@brainlab.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FES Super Extends Partnership with SS&C28.5.2025 00:13:00 CEST | Press release

SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced the Fire and Emergency Services Superannuation Fund (“FES Super”) has signed a long-term agreement to extend its existing partnership with SS&C. The renewal reinforces SS&C’s leadership and continued growth in the Australian superannuation market, following several recent strategic wins in the region. FES Super leverages SS&C Bluedoor, a cloud-hosted registry platform, to manage its administration needs. The platform enables real-time automation and straight-through processing, helping streamline operations and improving member experiences. SS&C also provides member digital and reporting services to the fund. “Our top priority is acting in the best interests of our members,” said Adrian Rutter, Fund Secretary at FES Super. “SS&C’s flexible, customizable tools and consistent service enable us to continue doing just that. By leveraging Bluedoor’s integration capabilities and cloud-native services, we can efficiently deliver

Perma-Pipe International Holdings, Inc. Announces New Contract Award in Qatar27.5.2025 21:48:00 CEST | Press release

Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH) today announced that it has received its first project award to be executed in Qatar since the announcement of the intent to mobilize there. The project will be for USD $2.4 million and will utilize Perma-Pipe’s fabrication capabilities and the XTRU-THERM® insulation system, a spray-applied polyurethane foam jacketed with a high-density polyethylene casing. Adham Sharkawy, Senior Vice President of Perma-Pipe’s MENA region, remarked, “In response to this important award, we will begin executing the project from a temporary facility in Doha, ensuring timely delivery and uninterrupted service to our client. Simultaneously, we are advancing the construction of our permanent facility in Qatar, which will serve as a long-term base for our regional operations. We are deeply grateful to our customers for their continued trust and confidence in Perma-Pipe’s capabilities.” Saleh Sagr, President, commented, “Expanding in Doha has been an impo

Galderma Intends to Buy Back approximately 2.4 Million Shares in the Context of the Accelerated Bookbuild Offering by EQT, ADIA and Auba27.5.2025 17:46:00 CEST | Press release

Galderma Group AG (SWX:GALD): Ad hoc announcement pursuant to Art. 53 LR Galderma intends to repurchase approximately 2.4 million shares in the context of the accelerated bookbuild offering of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (“ADIA”) and Auba Investment Pte. Ltd. (“Auba”) announced today The repurchased shares will be held in treasury and financed by existing liquidity at hand Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it intends to repurchase approximately 2.4 million Galderma shares in the context of an accelerated bookbuilding offering (“ABO”) of approximately 16.7 million Galderma shares (approximately 7% of Galderma’s share capital) by EQT, ADIA and Auba. Galderma will participate in the ABO at the same price per share which will be determined in the bookbuilding. The repurchased shares will be financed by Galderma’s existing liquidity on hand and will not affect the company’s ability to de

New South Wales Minister for Industry and Trade Visits Novotech Seoul Office to Strengthen Clinical Trial Collaboration27.5.2025 17:44:00 CEST | Press release

Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase, was honored to welcome The Hon. Anoulack Chanthivong, New South Wales (NSW) Minister for Industry and Trade, to its Seoul office on May 19. The Minister’s visit highlights a deepening collaboration between South Korea and Australia in the field of clinical research and highlights the strategic importance of cross-border partnerships in advancing global drug development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250527294947/en/ Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase, was honored to welcome The Hon. Anoulack Chanthivong,

LambdaTest Introduces Automation MCP Server to Revolutionize Test Failure Triaging27.5.2025 17:00:00 CEST | Press release

~New server connects AI assistants directly to test execution data, streamlining debugging and accelerating development~ LambdaTest, a unified agentic AI and cloud engineering platform, has announced the launch of its Automation MCP Server, a breakthrough solution designed to simplify and accelerate the process of triaging test failures. By enabling direct integration between AI assistants and LambdaTest’s test execution data, the Automation MCP Server empowers developers and QA engineers to investigate and resolve issues faster, without leaving their integrated development environment (IDE). The Automation MCP Server offers a seamless interface within the IDE, allowing users to access and analyze real-time test data with ease. With intelligent root cause analysis, the MCP server can quickly identify the underlying reasons for test failures and take immediate action to fix the underlying code. This results in fewer debugging cycles and faster release times. The server also enhances aut

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye